Grifols nabs Talecris in $4B buyout deal

Spain's Grifols has struck a $4 billion deal to buy Talecris Biotherapeutics, finally delivering a premium return for the investment groups that backed the Research Triangle Park, NC-based biotech. Talecris shareholders get a mix of $19 a share in cash along with stock--a combo package that offers a 53 percent premium over Talecris' 30-day average.

Grifols gets a U.S. biotech that was spun out of Bayer five years ago when Cerberus and Ampersand Ventures bought up the plasma business. For Talecris, which makes and develops blood plasma drugs, it's the second time at the M&A altar. Australia's CSL had made a concerted effort to buy the company for $3.1 billion back in 2008, but antitrust regulators derailed that effort. This time around analysts say that the merger has a good chance of getting a green flag from regulators, as Grifols has minimal operations in the country.

Grifols gets Talecris plasma collection operations around the U.S., which will help it shave significant costs from its own work in plasma collection, manufacturing and R&D. Talecris booked slightly more than $1.5 billion in revenue last year.

- check out Grifols' release
- read the story from the New York Times
- here's the report from the Wall Street Journal

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.